Please assess the completion status of the following clinical trial:

Trial Title: Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female aged 18 - 49 years or \>= 65 years~* Give written informed consent~* Females have a negative urine test for pregnancy before vaccination and use birth control during 28 day study period~* Willing to receive the unlicensed (VAX128) vaccine given as an i.m. injection~* Willing to provide multiple blood specimens collected by venipuncture~Exclusion Criteria:~* Chronic illness that would interfere with the subject's participation in the study or interpretation of the study results.~* Impaired immune responsiveness~* Received drugs effecting the immunity~* Received or plan to receive a nonstudy vaccine within 30 days prior to vaccination and during the study, including licensed influenza vaccines.~* History of anaphylactic type reaction to injected vaccines.~* History of drug abuse in the year prior to screening.~* History of Guillain-Barré Syndrome.~* Receipt or donation of blood products~* Acute disease within 72 hours prior to vaccination~* History of heart or lung disease~* Has other conditions that might interfere with study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VAX128 (Type: EXPERIMENTAL): Novel H1N1 Influenza vaccine
- Placebo (Type: PLACEBO_COMPARATOR): one IM injection

Based on this trial design, predict the completion outcome and termination type (if applicable).